Our discovery of a specific REGγ-dependent pathway to tune NFκB activity via IκBɛ may provide an opportunity to develop new molecules targeting the non-canonical (11S Cap) proteasome degradation pathway to attenuate but not abolish NFκB as an alternative therapeutic strategy for IBD. The gene discussed is NFKB1; the disease is inflammatory bowel disease.